Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudio Gasperini

Showing results (51-60 of 203) with videos related to

Pageof 21
Sort By:
Neurology and Therapy|August 2, 2017
A Comprehensive Review on Copemyl<sup>®</sup>Pietro Annovazzi, Antonio Bertolotto, Vincenzo Brescia Morra, et al.
Clinical Neuropharmacology|June 4, 2008
Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa studyAlessandra Lugaresi, Valentina Durastanti, Claudio Gasperini, et al.
Neurology|July 24, 2019
Effect of dalfampridine on information processing speed impairment in multiple sclerosisLaura De Giglio, Francesca De Luca, Flavia Gurreri, et al.
World Neurosurgery|October 6, 2022
Is Mechanical Thrombectomy or Thrombolysis Universally Cost-Effective? A Systematic Review of the LiteratureGianluca De Rubeis, Sebastiano Fabiano, Luca Bertaccini, et al.
Journal of Neurology|August 10, 2025
The use of high-efficacy disease-modifying therapies in multiple sclerosis: recommendations from an expert Delphi consensusMassimo Filippi, Maria Pia Amato, Diego Centonze, et al.
Molecular Neurobiology|November 10, 2016
Serum Compounds of Energy Metabolism Impairment Are Related to Disability, Disease Course and Neuroimaging in Multiple SclerosisGiacomo Lazzarino, Angela M Amorini, Axel Petzold, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 25, 2017
Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosisCarla Tortorella, Vita Direnzo, Maddalena Ruggieri, et al.
Journal of Neurology|May 24, 2022
Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinionMassimo Filippi, Maria Pia Amato, Diego Centonze, et al.
Annals of Clinical and Translational Neurology|February 3, 2021
Dynamics of pseudo-atrophy in RRMS reveals predominant gray matter compartmentalizationNicola De Stefano, Antonio Giorgio, Giordano Gentile, et al.
Cells|June 7, 2019
Distinct Expression of Inflammatory Features in T Helper 17 Cells from Multiple Sclerosis PatientsAlessia Capone, Manuela Bianco, Gabriella Ruocco, et al.
Pageof 21

Showing results (51-60 of 203) with videos related to

Sort By:
Pageof 21
Neurology and Therapy|August 2, 2017
A Comprehensive Review on Copemyl<sup>®</sup>Pietro Annovazzi, Antonio Bertolotto, Vincenzo Brescia Morra, et al.
Clinical Neuropharmacology|June 4, 2008
Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa studyAlessandra Lugaresi, Valentina Durastanti, Claudio Gasperini, et al.
Neurology|July 24, 2019
Effect of dalfampridine on information processing speed impairment in multiple sclerosisLaura De Giglio, Francesca De Luca, Flavia Gurreri, et al.
World Neurosurgery|October 6, 2022
Is Mechanical Thrombectomy or Thrombolysis Universally Cost-Effective? A Systematic Review of the LiteratureGianluca De Rubeis, Sebastiano Fabiano, Luca Bertaccini, et al.
Journal of Neurology|August 10, 2025
The use of high-efficacy disease-modifying therapies in multiple sclerosis: recommendations from an expert Delphi consensusMassimo Filippi, Maria Pia Amato, Diego Centonze, et al.
Molecular Neurobiology|November 10, 2016
Serum Compounds of Energy Metabolism Impairment Are Related to Disability, Disease Course and Neuroimaging in Multiple SclerosisGiacomo Lazzarino, Angela M Amorini, Axel Petzold, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 25, 2017
Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosisCarla Tortorella, Vita Direnzo, Maddalena Ruggieri, et al.
Journal of Neurology|May 24, 2022
Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinionMassimo Filippi, Maria Pia Amato, Diego Centonze, et al.
Annals of Clinical and Translational Neurology|February 3, 2021
Dynamics of pseudo-atrophy in RRMS reveals predominant gray matter compartmentalizationNicola De Stefano, Antonio Giorgio, Giordano Gentile, et al.
Cells|June 7, 2019
Distinct Expression of Inflammatory Features in T Helper 17 Cells from Multiple Sclerosis PatientsAlessia Capone, Manuela Bianco, Gabriella Ruocco, et al.
Pageof 21